Related Experiment Videos
Treating acute bronchiolitis associated with RSV
Robert William Prasaad Steiner1
1Department of Family and Community Medicine, University of Louisville School of Medicine, Louisville, Kentucky 40202, USA. r.steiner@louisville.edu
Insights
Supportive care is key for infant bronchiolitis from respiratory syncytial virus (RSV). While some treatments show limited effectiveness, infection control measures can reduce hospital-acquired RSV infections.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pulmonology
Background:
- Bronchiolosis is a common viral respiratory infection in infants, primarily caused by respiratory syncytial virus (RSV).
- Current management focuses on supportive care, but the efficacy of various pharmacological interventions remains under investigation.
- Identifying high-risk infants is crucial for determining appropriate levels of care and potential hospitalization.
Purpose of the Study:
- To review current treatment strategies for infants with respiratory syncytial virus (RSV) bronchiolitis.
- To evaluate the effectiveness of different therapeutic interventions, including bronchodilators, corticosteroids, and prophylactic agents.
- To highlight the importance of infection control in preventing nosocomial RSV transmission.
Main Methods:
- Literature review of studies on RSV bronchiolitis treatment.
- Analysis of clinical trial data and meta-analyses regarding treatment efficacy.
- Examination of guidelines and recommendations from health organizations.
Main Results:
- Supportive care, including oxygen, suctioning, and hydration, forms the cornerstone of treatment.
- Inhaled bronchodilators and nebulized epinephrine have not demonstrated consistent efficacy, though some sources suggest possible effectiveness.
- Corticosteroid use is controversial due to inconsistent meta-analysis results.
- Prophylaxis with palivizumab can reduce hospitalizations in high-risk infants but faces challenges in administration and cost.
- Infection-control measures are effective in reducing RSV transmission in healthcare settings.
Conclusions:
- Supportive care remains the primary treatment for RSV bronchiolitis.
- The efficacy of bronchodilators, epinephrine, and corticosteroids is not definitively established and warrants further research.
- Prophylactic options exist for high-risk infants but are limited by practical and economic factors.
- Implementing infection-control strategies is vital for preventing the spread of RSV in clinical environments.
Abstract:
Treatment for infants with bronchiolitis caused by respiratory syncytial virus (RSV) includes supplemental oxygen, nasal suctioning, fluids to prevent dehydration, and other supportive therapies. High-risk children who should be hospitalized include those younger than three months and those with a preterm birth, cardiopulmonary disease, immunodeficiency, respiratory distress, or inadequate oxygenation. Inhaled beta2-agonist bronchodilators, the anticholinergic agent ipratropium bromide, and nebulized epinephrine have not been shown to be effective for treating RSV bronchiolitis. However, the Agency for Healthcare Research and Quality states that nebulized epinephrine and nebulized ipratropium bromide are possibly effective. The appropriate use of corticosteroids remains controversial. They may provide some benefit but meta-analyses of clinical trial results are inconsistent. Prophylaxis with RSV intravenous immune globulin or palivizumab, a human monoclonal antibody, can reduce hospitalization rates in high-risk patients, although difficulties with administering the medications and high costs may preclude their widespread use. The use of common infection-control measures can reduce nosocomial transmission of RSV infections.